| Literature DB >> 34486728 |
Danja Sarink1, Kami K White1, Lenora W M Loo2, Anna H Wu3, Lynne R Wilkens1, Loïc Le Marchand1, Song-Yi Park1, V Wendy Setiawan3, Melissa A Merritt1.
Abstract
There are racial/ethnic differences in the incidence of hormone receptor positive and negative breast cancer. To understand why these differences exist, we investigated associations between hormone-related factors and breast cancer risk by race/ethnicity in the Multiethnic Cohort (MEC) Study. Among 81 511 MEC participants (Native Hawaiian, Japanese American, Latina, African American and White women), 3806 estrogen receptor positive (ER+) and 828 ER- incident invasive breast cancers were diagnosed during a median of 21 years of follow-up. We used Cox proportional hazards regression models to calculate associations between race/ethnicity and breast cancer risk, and associations between hormone-related factors and breast cancer risk by race/ethnicity. Relative to White women, ER+ breast cancer risk was higher in Native Hawaiians and lower in Latinas and African Americans; ER- disease risk was higher in African Americans. We observed interaction with race/ethnicity in associations between oral contraceptive use (OC; Pint .03) and body mass index (BMI; Pint .05) with ER+ disease risk; ever versus never OC use increased risk only in Latinas and positive associations for obese versus lean BMI were strongest in Japanese Americans. For ER- disease risk, associations for OC use, particularly duration of use, were strongest for African Americans (Pint .04). Our study shows that associations of OC use and obesity with ER+ and ER- breast cancer risk differ by race/ethnicity, but established risk factors do not fully explain racial/ethnic differences in risk. Further studies are needed to identify factors to explain observed racial/ethnic differences in breast cancer incidence.Entities:
Keywords: breast cancer; estrogen receptor; hormone-related risk factors; race/ethnicity; risk
Mesh:
Substances:
Year: 2021 PMID: 34486728 PMCID: PMC8627491 DOI: 10.1002/ijc.33795
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396